7 Most Profitable Biotech Stocks To Buy Right Now

5. Argenx SE (NASDAQ:ARGX)

Latest Net Income: $833.04 million 

Argenx SE (NASDAQ:ARGX) stands fifth among the most profitable stocks. It is a biotechnology company specializing in antibody-based therapies for autoimmune diseases and cancer. Its flagship product, VYVGART, treats conditions like myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. What sets the company apart is its proprietary SIMPLE Antibody technology, which enhances therapeutic antibody functionality, enabling the development of innovative treatments that target immune system pathways.

Argenx SE (NASDAQ:ARGX) delivered strong financial results for Q4 2024 and the full year, reporting $737 million in product net sales for Q4 and $2.2 billion for the year. Total operating income reached $761 million in Q4 and $2.3 billion for the year, while net profit stood at $774 million in Q4 and $833 million for 2024. The company ended the year with a solid cash position of $3.4 billion.

Argenx SE (NASDAQ:ARGX) expanded its reach to over 10,000 patients globally across three approved indications, which was driven by a 98% year-over-year growth in product net sales. Its flagship product, VYVGART, has had a major impact on the treatment of generalized myasthenia gravis (gMG) and is seeing strong early adoption for chronic inflammatory demyelinating polyneuropathy (CIDP).

Looking ahead, the corporation is advancing its Vision 2030 strategy with ambitious goals: treating 50,000 patients, securing 10 labeled indications, and progressing five pipeline candidates to Phase 3. The company currently has 20 active clinical trials, including 10 Phase 3 and 10 Phase 2 studies, positioning it for sustained growth.

Argenx SE (NASDAQ:ARGX) expects 2025 to be its first profitable year, with projected R&D and SG&A expenses of $2.5 billion, reflecting its commitment to innovation. Regulatory progress continues, with a positive CHMP recommendation for the VYVGART pre-filled syringe in the EU and an FDA decision expected by April 10, 2025, potentially broadening market reach and improving treatment accessibility.